Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection

Zaucha, G. M., Jahrling, P. B., Geisbert, T. W., Swearengen, J. R. & Hensley, L. The pathology of experimental aerosolized monkeypox virus infection in cynomolgus monkeys (Macaca fascicularis). Lab. Invest. 81, 1581–1600 (2001)

Stittelaar, K. J. et al. Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus. J. Virol. 79, 7845–7851 (2005)

Smith, G. L. & McFadden, G. Smallpox: anything to declare? Nature Rev. Immunol. 2, 521–527 (2002)

Breman, J. G. & Arita, I. The confirmation and maintenance of smallpox eradication. N. Engl. J. Med. 303, 1263–1273 (1980)

Lewis-Jones, S. Zoonotic poxvirus infections in humans. Curr. Opin. Infect. Dis. 17, 81–89 (2004)

Grabenstein, J. D. & Winkenwerder, W. Jr US military smallpox vaccination program experience. J. Am. Med. Assoc. 289, 3278–3282 (2003)

De Clercq, E. & Neyts, J. Therapeutic potential of nucleoside/nucleotide analogues against poxvirus infections. Rev. Med. Virol. 14, 289–300 (2004)

Finkel, E. Australia. Engineered mouse virus spurs bioweapon fears. Science 291, 585 (2001)

Stanford, M. M. & McFadden, G. The ‘supervirus’? Lessons from IL-4-expressing poxviruses. Trends Immunol. 26, 339–345 (2005)

Bray, M. & Roy, C. J. Antiviral prophylaxis of smallpox. J. Antimicrob. Chemother. 54, 1–5 (2004)

Buller, R. M. et al. Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model. Virology 318, 474–481 (2004)

Quenelle, D. C., Collins, D. J. & Kern, E. R. Efficacy of multiple- or single-dose cidofovir against vaccinia and cowpox virus infections in mice. Antimicrob. Agents Chemother. 47, 3275–3280 (2003)

Roy, C. J., Baker, R., Washburn, K. & Bray, M. Aerosolized cidofovir is retained in the respiratory tract and protects mice against intranasal cowpox virus challenge. Antimicrob. Agents Chemother. 47, 2933–2937 (2003)

Smee, D. F., Bailey, K. W. & Sidwell, R. W. Comparative effects of cidofovir and cyclic HPMPC on lethal cowpox and vaccinia virus respiratory infections in mice. Chemotherapy 49, 126–131 (2003)

Neyts, J., Leyssen, P., Verbeken, E. & De Clercq, E. Efficacy of cidofovir in a murine model of disseminated progressive vaccinia. Antimicrob. Agents Chemother. 48, 2267–2273 (2004)

Smee, D. F., Bailey, K. W., Wong, M. H., Wandersee, M. K. & Sidwell, R. W. Topical cidofovir is more effective than is parenteral therapy for treatment of progressive vaccinia in immunocompromised mice. J. Infect. Dis. 190, 1132–1139 (2004)

De Clercq, E. Cidofovir in the therapy and short-term prophylaxis of poxvirus infections. Trends Pharmacol. Sci. 23, 456–458 (2002)

Bronze, M. S. & Greenfield, R. A. Therapeutic options for diseases due to potential viral agents of bioterrorism. Curr. Opin. Investig. Drugs 4, 172–178 (2003)

Prichard, M. N. & Kern, E. R. Orthopoxvirus targets for the development of antiviral therapies. Curr. Drug Targets Infect. Disord. 5, 17–28 (2005)

Wharton, M. et al. Recommendations for using smallpox vaccine in a pre-event vaccination program. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm. Rep. 52, 1–16 (2003)

Yang, G. et al. An orally bioavailable anti-poxvirus compound (ST-246) that inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge. J. Virol. 79, 13139–13149 (2005)

Reeves, P. M. et al. Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases. Nature Med. 11, 731–739 (2005)

Yang, H. et al. Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction. J. Clin. Invest. 115, 379–387 (2005)

McFadden, G. Gleevec casts a pox on poxviruses. Nature Med. 11, 711–712 (2005)

Balzarini, J. et al. 6-[2-phosphonomethoxy)alkoxy]-2,4-diaminopyrimidines: a new class of acyclic pyrimidine nucleoside phosphonates with antiviral activity. Nucleosides Nucleotides Nucleic Acids 23, 1321–1327 (2004)

Neyts, J., Leyssen, P., De Clercq, E. & Holy, A. Effects of (S)-HPMPDAP and (S)-HPMPO-DAPym on vaccinia virus infections in mice. Antiviral Res. 62, 109 (2004)

Rosenthal, S. R. & Clifford, J. C. Development of vaccines for bio-warfare agents. Dev. Biol. (Basel) 110, 99–105 (2002)

Massoudi, M. S., Barker, L. & Schwartz, B. Effectiveness of postexposure vaccination for the prevention of smallpox: results of a delphi analysis. J. Infect. Dis. 188, 973–976 (2003)

Cundy, K. C. Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin. Pharmacokinet. 36, 127–143 (1999)

Meyer, H. et al. Outbreaks of disease suspected of being due to human monkeypox virus infection in the Democratic Republic of Congo in 2001. J. Clin. Microbiol. 40, 2919–2921 (2002)